- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Angus Worthing: Congressional Budget Allocation for Healthcare
Angus Worthing, MD, FACR, FACP, discusses the need for adequate funding for the FDA and healthcare.
Transcript:
Former CMS head Andy Slavitt recently spoke about the need for a “champion” in Congress who can ensure sufficient budget allocation for healthcare. Do you agree?
I do, I think Andy Slavitt has a lot of good ideas about healthcare reform in the US. I think we do need champions in Congress right now to help fix the system. One important part, as we talk about biosimilars, is that we need to support the Food and Drug Administration as it hires experts that are needed to both review and approve safe and effective drugs—that’ll be biosimilars that we use, but also that will create guidances for manufacturers to come up with the right clinical trials and clinical trial designs to prove and give confidence to doctors and patients that the drugs work effectively. So, I think it’s important to fund the agency appropriately and we need champions in Congress to do that. Fortunately, this Congress has already authorized the Biosimilar User Fee Agreement of 2017, and the President signed it into law. So, that’s an important first step to that process.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
